Strongbridge Biopharma plc

Strongbridge Biopharma — Investor Presentation (September 2020)

42 slides from Strongbridge Biopharma's investor presentation, Sep 8, 2020

  1. Slide 1: Strongbridge Biopharma plc September 2020

    STRONGBRIDGE BIOPHARMA PLC SEPTEMBER 2020

  2. Slide 2: Forward-looking statements

    Forward-looking statements This document contains forward‐looking statements relating to the Company’s strategy, objectives, business development plans, financial position, clinical development, regulatory plans and revenue guidance. All statements other than statements of historical facts included

  3. Slide 3: Strongbridge: revenue-generating, rare disease-focused company with potential new product launch

    Strongbridge: A revenue-generating, rare disease-focused company with commercial infrastructure and a potential new product launch opportunity 3 Rare disease commercial infrastructure and experience with launching and growing rare disease drugs Development infrastructure to manage global clinical tr

  4. Slide 4: Three-product rare-disease portfolio

    Strongbridge has a three-product, rare-disease portfolio 4 Positive results from two Phase 3 studies NDA submission anticipated Q1 2021 10-month PDUFA review expected Launch Q1 2022 if approved Novel, patented, extended release formulation is under evaluation in nonclinical disease models potentiall

  5. Slide 5: Management team experience

    Management team experience 5 Robert Lutz Scott Wilhoit Chief Financial Officer Chief Commercial Officer John Johnson Chief Executive Officer • Company Group Chairman, Worldwide Biopharmaceuticals - J&J • CEO - Imclone Systems • President of Global Oncology - Eli Lilly • Multiple Board and Chairman R

  6. Slide 6: RECORLEV (levoketoconazole) in Phase 3 development for Cushing's syndrome

    RECORLEV (levoketoconazole) In Phase 3 development for Cushing’s syndrome 6 The safety and efficacy of Recorlev (levoketoconazole) for treatment of endogenous Cushing's syndrome has not been established.

  7. Slide 7: Endogenous Cushing's syndrome is a serious rare disease

    Endogenous Cushing’s syndrome is a serious rare disease *According to a retrospective analysis of claims from a large U.S, commercial health plan (885 selected Cushing’s disease cases and 2,655 matched controls without Cushing’s disease) from 2007 to 2011. 7 Affects the whole body Endogenous Cushing

  8. Slide 8: Estimated ~8,000 CS patients in U.S. are Rx-treated

    An estimated ~8,000 CS patients in the U.S. are Rx-treated* ~3,200 of whom are not well controlled** Abbreviation: Rx= prescription drug * Source: Secondary literature and company sponsored research ** A07. Of your endogenous Cushing’s patients currently receiving pharmacological therapy, what perce

  9. Slide 9: Levoketoconazole, an enantiomer of ketoconazole, and cortisol inhibition

    Levoketoconazole, an enantiomer of ketoconazole, comprises virtually all the cortisol inhibition activity of ketoconazole* *Auchus RJ, Wu JL, Peng HM “2S,4R-Ketoconazole is the Relevant Enantiomer of Ketoconazole for Cortisol Synthesis Inhibition: Steroidogenic P450s Inhibition Involves Multiple Mec

  10. Slide 10: Phase 3 program for Recorlev

    Phase 3 program for Recorlev: includes two phase 3 studies with positive results 10 Phase 3 Study Study Design Patients Status SONICS1 Single-arm, open-label, dose-titration study in adults with Cushing’s syndrome (CS) 94 patients enrolled in dose- titration phase • Completed with statistically sign

  11. Slide 11: SONICS phase 3 open-label single-arm study

    SONICS, a successfully completed phase 3, multi- center, open-label, single-arm study *1 subject did not enter extended evaluation **mUFC= mean urinary free cortisol 11 94 enrolled in dose titration 77 entered maintenance 61 completed maintenance 46 completed extended evaluation 17 Discontinued 6 ad

  12. Slide 12: SONICS primary endpoint was statistically significant

    SONICS primary endpoint was statistically significant *Based on mixed-effects, repeated-measures model with underlying binomial distribution and logit link function, adjusted for baseline covariates. **Abbreviations: ITT= Intent to Treat population; mUFC= mean urinary free cortisol; ***Data based on

  13. Slide 13: Recorlev improved key cardiovascular risk biomarkers in CS

    Importantly, Recorlev improved key biomarkers of cardiovascular risk in CS *Hochberg adjustment applied to p-values to control type 1 error †Mean reductions from baseline based on least squares mean changes from repeated- measures model adjusted for baseline covariates 13 Outcome Measure Baseline Me

  14. Slide 14: Summary of key safety findings in SONICS

    Summary of key safety findings in SONICS *Includes all alanine aminotransferase (ALT) increases reported as an adverse event regardless of level or relationship to drug. A subset of these ALT increased events was also reported as adverse events of special interest. 14 Most Frequent Treatment-Emergen

  15. Slide 15: LOGICS: phase 3 randomized-withdrawal trial

    LOGICS: a phase 3, double-blind, placebo-controlled, randomized-withdrawal trial * Subjects who directly rolled over into LOGICS from SONICS and were on a stable therapeutic dose for 12 weeks prior to screening did not require titration-maintenance ** Early rescue can happen at any time during rando

  16. Slide 16: LOGICS primary endpoint results

    The enrolled study population had baseline characteristics comparable to those in the SONICS study, representative of a medically treated CS population with moderate to severe hypercortisolemia LOGICS showed that 54.5% more patients lost response on placebo than on levoketoconazole (p-value: 0.0002)

  17. Slide 17: Cholesterol measures differed between active and placebo

    Cholesterol measures showed a significant difference between active and placebo despite a maximum treatment duration of only approximately eight weeks RW1 Phase Baseline Mean Value Mean Change from Baseline at End of RW1 Phase Adjusted p- value2 Outcome Measure L-KTZ Placebo L-KTZ Placebo Fasting Gl

  18. Slide 18: Adverse events in LOGICS comparable to SONICS

    Adverse events during levoketoconazole treatment in LOGICS were generally comparable to those seen in SONICS 18 Treatment-Emergent Adverse Events During Levoketoconazole Use (Phases combined) Nausea 29% Hypokalemia 28% Headache 21% Hypertension 19% Diarrhea 15% Treatment-emergent events with inciden

  19. Slide 19: Safety measures in LOGICS comparable to SONICS

    Safety measures in LOGICS were generally comparable to those seen in SONICS 19 Liver Test Results During Levoketoconazole Use (Phases combined) (Worst observed value for ALT) ALT > 3x ULN (includes those > 5x ULN) 11.4% ALT > 5x ULN 3.8% Total bilirubin values > 1.5x ULN 0.0% N=79* No Hy’s Law, no t

  20. Slide 20: Recorlev could be launched in U.S. Q1 2022 if approved

    Recorlev could be launched in U.S. Q1 2022 if approved 20 NDA submission ~Q1 2021 ~10-month PDUFA review The safety and efficacy of Recorlev (levoketoconazole) for treatment of endogenous Cushing's syndrome has not been established. PDUFA date ~Q4 2021 or Q1 2022 U.S. Launch ~Q1 2022

  21. Slide 21: Recorlev Commercial Opportunity

    RECORLEV COMMERCIAL OPPORTUNITY 21 The safety and efficacy of Recorlev (levoketoconazole) for treatment of endogenous Cushing's syndrome has not been established.

  22. Slide 22: U.S. market assessment indicates significant commercial opportunity

    U.S. market assessment indicates Recorlev could be a significant commercial opportunity Source: Company sponsored research *Average Number of Endogenous CS Pts w/o Malignant cause in Past Six Months 22 Strongbridge CS Market Assessment CS Market Assessment Summary Qualitative HCP Research − 13 Endoc

  23. Slide 23: Fragmented CS prescribing market dominated by unapproved products

    Fragmented CS prescribing market – dominated by unapproved CS products* Source: Company sponsored research Signifor and Signifor LAR are owned by Recordati; Korlym is owned by Corcept * Isturisa was approved on March 9th 2020.after the market research was conducted **2020 Corcept guidance B08. Of yo

  24. Slide 24: Current treatment options have limitations

    Current treatment options have limitations Source: Product Labeling 24 Name Target(s) Dosing U.S. Regulatory Status Warnings/Precautions in Label FDA Approved Products - Oral Isturisa (osilodrostat) 11-β-hydroxylase Oral; BID Approved for adult patients with Cushing's disease form whom pituitary sur

  25. Slide 25: A need for new treatment options exists

    A need for new treatment options exists Source: Company sponsored research B02. When thinking of your endogenous Cushing’s syndrome patients that you have personally managed in the past six months, please indicate which of the following pharmacological therapies your patients have received. A07. Of

  26. Slide 26: Endocrinologists reacted positively to Recorlev clinical profile

    Endocrinologists had a positive reaction to the Recorlev clinical profile and indicated a likelihood to prescribe if approved Source: Company sponsored research D03. Based on this profile, what is your likelihood to prescribe Product Y? Please rate on scale from 1-9, with 1 being “Not at all likely”

  27. Slide 27: 40% of HCPs surveyed do not use ketoconazole

    40% of HCPs surveyed do not use ketoconazole Although Ketoconazole is currently the most prescribed treatment, there is a significant opportunity for Recorlev Source: Company sponsored research The safety and efficacy of Recorlev (levoketoconazole) for treatment of endogenous Cushing's syndrome has

  28. Slide 28: Recorlev and ketoconazole profiles

    Recorlev and ketoconazole profiles * The data set forth above is not based on directly comparable trials and/or studies ** Source: 1. Young et al. Eur J Endocrinol. 2018 Feb 22. pii: EJE-17-0886. doi: 10.1530/EJE-17-0886. [Epub ahead of print] 28 RECORLEV KETOCONAZOLE Indication Anticipated labeling

  29. Slide 29: Precedent established for CS branded pricing

    Precedent established for CS branded pricing* Source: Red Book, Signifor Prescribing Info, Signifor LAR Prescribing Information, Korlym Prescribing Information, Isturisa Prescribing Information * Wholesale/ Acquisition Cost ** Isturisa estimated annual cost based on maintenance dose range of 2mg-7mg

  30. Slide 30: Payers indicated willingness to cover Recorlev across tested price range

    Consistent with current branded CS products, Payers indicated a willingness to cover a product like Recorlev throughout the tested price range ($200k-$400k annually) Source: Company sponsored research; *Policy Reporter Commercial Lives, August,, 2020; Excludes Isturisa **Global Peak Sales *** 2020 e

  31. Slide 31: Well defined and efficient endocrinology call point

    Well defined and efficient Endocrinology call point 31 25-45 Field facing positions at launch* *Sales Representatives, Patient Access Managers and Medical Science Liaisons COEs and KOLs Ketoconazole prescribing High Volume CS prescribers Community Endos The safety and efficacy of Recorlev (levoketoc

  32. Slide 32: Key imperatives for a successful Recorlev launch

    Key imperatives for a successful Recorlev launch 32 Build on Established Strongbridge Commercial Capabilities Recorlev Launch Imperatives Establish Recorlev’s Unique Positioning & Value Proposition Communicate Recorlev’s Anticipated Differentiated Clinical Profile Leverage and Expand KOL and Patient

  33. Slide 33: Potential to capitalize on $2B+ total addressable annual market

    Recorlev represents the potential to capitalize on a $2B+ total addressable annual market 33 The safety and efficacy of Recorlev (levoketoconazole) for treatment of endogenous Cushing's syndrome has not been established. ~25,000 ~21,500 ~20,600 Prevalence of Endogenous Cushing’s syndrome in US ~3,20

  34. Slide 34: KEVEYIS (dichlorphenamide)

    KEVEYIS (dichlorphenamide) * FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis 34 The first and only FDA-approved therapy for primary periodic paralysis*

  35. Slide 35: Primary periodic paralysis: rare, chronic, genetic neuromuscular disorders

    Primary periodic paralysis: a spectrum of rare, chronic, genetic, neuromuscular disorders 35 1. Charles G, Zheng C, Lehmann-Horn F, Jurkatt-Rott, Levitt J. Characterization of hyperkalemic periodic paralysis: a survey of genetically diagnosed individuals. J Neurol. 2013;260:2606-2613. 2. Cannon SC.

  36. Slide 36: Treatment with Keveyis decreased weekly attack rates

    4.0 2.0 1.8 1.1 4.8 0.9 2.4 0.3 Study 2 Study 1 Treatment with Keveyis decreased weekly attack rates Keveyis is the first and only FDA-approved product indicated for the treatment of primary hyperkalemic and hypokalemic periodic paralysis and related variants Study 1: Sansone VA, et al. Neurology 20

  37. Slide 37: Keveyis provides revenue and commercial experience

    Keveyis provides revenue and commercial experience/expertise for Strongbridge 37 ~4,000 – 5,000* Diagnosed PPP patients in the United States Total addressable market is more than $500M annually We are attempting to extend Keveyis exclusivity by pursuing 12 patent applications 7.0 16.8 21.7 28.0 29.0

  38. Slide 38: IP & Financials

    IP & FINANCIALS 38

  39. Slide 39: Intellectual property and orphan exclusivity

    Intellectual property and orphan exclusivity Recorlev U.S. Exclusivity: At least 7 years from launch Keveyis U.S. Exclusivity: Expires August 2022 unless extended via IP efforts 39 Orphan Exclusivity EU EU RECORLEV VELDOREOTIDE KEVEYIS Intellectual Property U.S. Method of use: treating Cushing’s syn

  40. Slide 40: 2020 Keveyis revenue guidance and cash position

    2020 Keveyis revenue guidance $28M—$29M ~$60M Cash Cash and cash equivalents as of 6/30/20 $30M Debt Facility - $10M drawn at close - Up to $10M more available Q4 2020 based on positive Recorlev data - Up to an additional $10M available upon Recorlev approval and lender consent - No revenue or cash

  41. Slide 41: Near-term key priorities

    Near-term key priorities 41 • Submit an NDA for Recorlev to the U.S. FDA Q1 2021 • Launch planning • Achieve our updated full year 2020 guidance range of $28-$29M • Execute on life cycle opportunities underway for KEVEYIS • Manage expenses to achieve or exceed runway guidance of cash lasting through

  42. Slide 42: Strongbridge Biopharma plc

    STRONGBRIDGE BIOPHARMA PLC 42

Strongbridge Biopharma — Investor Presentation (September 2020) on 6ix